TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

1.224 Panda A et al. Management approach for bacterial and fungal corneal ulcers. Expert Rev Ophthalmol 2008;3:471-9. 1.225 Suwan-apichan O et al. Topical corticosteroids as adjunctive therapy for bacterial keratitis. Cochrane Database Syst Rev 2007;4:CD005430. 1.226 FlorCruz NV et al. Medical interventions for fungal keratitis. Cochrane Database Syst Rev 2008;1: CD004241. 1.227 Shukla PK et al. Mycotic keratitis: an overview of diagnosis and therapy. Mycoses 2008;51:183-99. 1.228 Prakash G et al. Evaluation of intrastromal injection of voriconazole as therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol 2008;146:56-9. 1.229 Dart JK et al. Acanthamoeba keratitis: diagnosis and treatment. Update 2009. Am J Ophthalmol 2009;148:487-99. 1.230 Hammersmith KM. Diagnosis and management of Acanthamoeba keratitis. Curr Opin Ophthalmol 2006;17:327-31. 1.231 Awwad ST et al. Updates in Acanthamoeba keratitis. Eye Contact Lens 2007;33:1-8. 1.232 Marciano-Cabral F et al. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 2003;16:273-307. 1.233 Seal D. Treatment of Acanthamoeba keratitis. Expert Rev Anti Infect Ther 2003;1:205-8. 1.234 Woods CR. Gonococcal infections in infants and young children. Semin Pediatr Infect Dis 2005;16: 258-70. 1.235 Rours IG et al. Chlamydia trachomatis as a cause of neonatal conjunctivitis in Dutch infants. Pediatrics 2008;121:e321-6. 1.236 Darville T. Chlamydia trachomatis infections in neonates and young children. Semin Pediatr Infect Dis 2005;16:235-44. 1.237 Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev 2004;20(suppl. 1):S90-5. 1.238 Butalia S et al. Does this patient with diabetes have osteomyelitis of the lower extremity? J Am Med Assoc 2008;299:806-13. 1.239 Dinh MT et al. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. Clin Infect Dis 2008;47:519-27. 1.240 Lipsky BA. Bone of contention: diagnosing diabetic foot osteomyelitis. Clin Infect Dis 2008;47:528- 30. 1.241 Senneville E et al. Needle puncture and transcutaneous bone biopsy cultures are inconsistent in patients with diabetes and suspected osteomyelitis of the foot. Clin Infect Dis 2009;48:888-93. 1.242 Senneville E et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis 2006;42:57-62. 1.243 Embil JM et al. Microbiological evaluation of diabetic foot osteomyelitis. Clin Infect Dis 2006:42:63-5. 1.244 Lavery LA et al. Validation of the Infectious Diseases Society of America‘s diabetic foot infection classification system. Clin Infect Dis 2007;44:562-5. 1.245 Cheer K et al. Managing complications of the diabetic foot. Br Med J 2009;339:1304-7. 1.246 Rao N et al. Optimising antimicrobial therapy in diabetic foot infections. Drugs 2007;67:195-214. 1.247 Cavanagh PR et al. Treatment for diabetic foot ulcers. Lancet 2005;366:1725-35. 1.248 Boulton AJ et al. Neuropathic diabetic foot ulcers. N Engl J Med 2004;351:48-55. 1.249 Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis 2004;39(suppl. 2):S104-14. 1.250 Berendt AR et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev 2008;24(suppl. 1):S145-61. 1.251 Wraight PR et al. Creation of a multidisciplinary, evidence based, clinical guideline for the assessment, investigation and management of acute diabetes related foot complications. Diabet Med 2005; 22:127-36. 1.252 Lipsky BA et al. Diagnosis and management of diabetic foot infections. Clin Infect Dis 2004;39:885- 910. 1.253 Cohen SH et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55. 1.254 Bauer MP et al. European Society for Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance for Clostridium difficile infection. Clin Microbiol Infect 2009;15:1067-79. 1.255 Gerding DN et al. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl. 1):S32- 42. 1.256 DuPont HL et al. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr Opin Infect Dis 2008;21:500-7. 1.257 Kelly CP et al. Clostridium difficile. More difficult than ever. N Engl J Med 2008;359:1932-40. 1.258 Bryant K et al. Clostridium difficile infections in children. Pediatr Infect Dis J 2009;28:145-6. 1.259 Shannon-Lowe J et al. Prevention and medical management of Clostridium difficile infection. Br Med J 2010;340:c1296. 1.260 Gerding DN et al. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl. 1):S32- 42. 1.261 Bartlett JG. Antibiotic associated diarrhea. N Engl J Med 2002;346:334-9. 1.262 Yassin SF et al. Clostridium difficile associated diarrhea and colitis. Mayo Clin Proc 2001;76:725-30. 1.263 Aslam S et al. Treatment of Clostridium difficile associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549-57. 1.264 Starr J. Clostridium difficile associated diarrhoea: diagnosis and treatment. Br Med J 2005;331:498- 501. 1.265 Bauer MP et al. Clostridium difficile: controversies and approaches to management. Curr Opin Infect Dis 2009;22:517-24. 1.266 Miller MA. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 2007;45 (suppl. 2):S122-8. 1.267 Voth DE et al. Clostridum difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005;18:247-63. 1.268 Hoge Gezondheidsraad. Belgische aanbevelingen voor de beheersing en preventie van infecties met Clostridium difficile in acute ziekenhuizen en in woon- en zorgcentra. Available at: https://portal. health.fgov.be/pls/portal/docs/PAGE/INTERNET_PG/HOMEPAGE_MENU/ABOUTUS1_MENU/INSTI TUTIONSAPPARENTEES1_MENU/HOGEGEZONDHEIDSRAAD1_MENU/BROCHURES1_HIDE/B ROCHURES1_DOCS/HGR_8365_NL.PDF. Accessed on August 21 st 2010. 1.269 Conseil Supérieur de la Santé. Recommandations belges pour le contrôle et la prévention des infec-
tions à Clostridium difficile dans les hôpitaux aigus et dans les maisons de repos et de soins. Available at: https://portal.health.fgov.be/pls/portal/docs/PAGE/INTERNET_PG /HOMEPAGE_MENU/ A BOUTUS1_MENU/ INSTITUTIONSAPPARENTEES1_MENU/HOGEGEZONDHEIDSRAAD1_MENU /BROCHURES1_HIDE/BROCHURES1_DOCS/CSS_8365_FR.PDF. Accessed on August 21 st 2010. 1.270 Gerding DN et al. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008;46(suppl. 1):S43-9. 1.271 Dubberke ER et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(suppl. 1):S81-92. 1.272 Vonberg RP et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008;14(suppl. 5):2-20. 1.273 Owens RC et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008;46(suppl. 1):S19-31. 1.274 Dial S et al. Use of gastric acid suppressive agents and the risk of community acquired Clostridium difficile associated disease. J Am Med Assoc 2005;294:2989-95. 1.275 Wilcox MH et al. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008;62:388-96. 1.276 Crobach MJ et al. European Society for Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile infection. Clin Microbiol Infect 2009;15:1053-66. 1.277 Bartlett JG et al. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl. 1):S12-18. 1.278 Kelly CP et al. A 76-year old man with recurrent Clostridium difficile associated diarrhea: review of Clostridium difficile Infection. J Am Med Assoc 2009;301:954-62. 1.279 Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009;58:403-10. 1.280 Pépin J et al. Management and outcomes of a first recurrence of Clostridium difficile associated disease in Quebec, Canada. Clin Infect Dis 2006;42:758-64. 1.281 Kyne L et al. Recurrent Clostridium difficile diarrhoea. Gut 2001;49:152-3. 1.282 McFarland LV et al. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769-75. 1.283 Wanahita A et al. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003;115:543-6. 1.284 Wanahita A et al. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 2002;34:1585-92. 1.285 Goorhuis A et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-70. 1.286 Kuijper EJ et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12(suppl. 6):2-18. 1.287 Delmée M et al. Epidemiology of Clostridium difficile toxinotype III, PCR-ribotype 027 associated disease in Belgium, 2006. Available at: http://www.eurosurveillance.org/ViewArticle. aspx?ArticleId= 3045. Accessed on August 21 st 2010. 1.288 Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006;145:758-764. 1.289 Blossom DB et al. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 2007;45:222-7. 1.290 Koo HL et al. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009;48:598-605. 1.291 Gerding DN. Antimotility agents for the treatment of Clostridium difficile infection: is the juice worth the squeeze? Clin Infect Dis 2009;48:606-8. 1.292 Al-Nassir WN et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile associated disease with metronidazole and vancomycin. Clin Infect Dis 2008;47:56-62. 1.293 Kuijper EJ et al. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin Infect Dis 2008;47:63-5. 1.294 Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007;3:CD004610. 1.295 Musher DM et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586-90. 1.296 Pépin J et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-7. 1.297 Gerding DN. Metronidazole for Clostridium difficile associated disease: is it okay for mom? Clin Infect Dis 2005;40:1598-600. 1.298 Zar FA et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7. 1.299 Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008;46:1489-92. 1.300 Pepin J. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic? Clin Infect Dis 2008;46:1493-8. 1.301 Apisarnthanarak A et al. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002;35:690-6. 1.302 Parkes GC et al. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficileassociated diarrhoea. Lancet Infect Dis 2009;9:237-44. 1.303 Hickson M et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. Br Med J 2007;335:80-4. 1.304 Johnson S et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-8. 1.305 Musher DM et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007;59:705-10. 1.306 Juang P et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile associated diarrhea. Am J Infect Control 2007;35:131-7. 1.307 Aas J et al. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003;36:580-5. 1.308 Högenauer C et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006;355:2418-26.
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5: of NICE guidance. Br Med J 2008;337
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58:
factor and other newly approved bio
Page 59 and 60:
cument E.DEF 8.1). Report of the Su
Page 61 and 62:
Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64:
new prediction equation. Ann Intern
Page 65 and 66:
14A.93 Sundar S et al. New treatmen
Page 67 and 68:
eview. Obstet Gynecol 2005;105:857-
Page 69 and 70:
2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72:
14B.4 Checkley AM et al. Eosinophil
Page 73 and 74:
18.12 Panel on Antiretroviral Thera
Page 75 and 76:
18.91 Lesho E. Evidence base for us
Page 77 and 78:
tients. J Antimicrob Chemother 2009
Page 79 and 80:
duct characteristics. Available at:
Page 81 and 82:
_Product_Information/human/000338/W
Page 83 and 84:
114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86:
North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88:
1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90:
21.358 Calabrese LH et al. Viral Ar
Page 91 and 92:
24. 21.452 Jeha LE et al. Long term
Page 93 and 94:
induced functional androgen deficie
Page 95 and 96:
25A.27 Conseil Supérieur de la San
Page 97 and 98:
product characteristics. Available
Page 99 and 100:
mortality after kidney transplantat
Page 101 and 102:
33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

Create successful ePaper yourself

Delete template?

Save as template?